Advertisement
Corrigendum
Open Access | 10.1172/JCI198274
Find articles by Oravecz-Wilson, K. in: PubMed | Google Scholar
Find articles by Lauder, E. in: PubMed | Google Scholar
Find articles by Taylor, A. in: PubMed | Google Scholar
Find articles by
Maneix, L.
in:
PubMed
|
Google Scholar
|
Find articles by
Van Nostrand, J.
in:
PubMed
|
Google Scholar
|
Find articles by Sun, Y. in: PubMed | Google Scholar
Find articles by Li, L. in: PubMed | Google Scholar
Find articles by Zhao, D. in: PubMed | Google Scholar
Find articles by Liu, C. in: PubMed | Google Scholar
Find articles by
Reddy, P.
in:
PubMed
|
Google Scholar
|
Published September 2, 2025 - More info
Tissue-intrinsic mechanisms that regulate severity of systemic pathogenic immune-mediated diseases, such as acute graft-versus-host disease (GVHD), remain poorly understood. Following allogeneic hematopoietic stem cell transplantation, autophagy, a cellular stress protective response, is induced in host nonhematopoietic cells. To systematically address the role of autophagy in various host nonhematopoietic tissues, both specific classical target organs of acute GVHD (intestines, liver, and skin) and organs conventionally not known to be targets of GVHD (kidneys and heart), we generated mice with organ-specific knockout of autophagy related 5 (ATG5) to specifically and exclusively inhibit autophagy in the specific organs. When compared with wild-type recipients, animals that lacked ATG5 in the gastrointestinal tract or liver showed significantly greater tissue injury and mortality, while autophagy deficiency in the skin, kidneys, or heart did not affect mortality. Treatment with the systemic autophagy inducer sirolimus only partially mitigated GVHD mortality in intestine-specific autophagy-deficient hosts. Deficiency of autophagy increased MHC class I on the target intestinal epithelial cells, resulting in greater susceptibility to damage by alloreactive T cells. Thus, autophagy is a critical cell-intrinsic protective response that promotes tissue tolerance and regulates GVHD severity.
Katherine Oravecz-Wilson, Emma Lauder, Austin Taylor, Laure Maneix, Jeanine L. Van Nostrand, Yaping Sun, Lu Li, Dongchang Zhao, Chen Liu, Pavan Reddy
Original citation: J Clin Invest. 2024;134(5):e167369. https://doi.org/10.1172/JCI167369
Citation for this corrigendum: J Clin Invest. 2025;135(17):e198274. https://doi.org/10.1172/JCI198274
The authors recently became aware of missing funding information in the original publication. An updated Acknowledgments section is provided below:
This work was supported by NIH grants (R01HL152605, P01HL149633, and R01CA217156 to PR; 1R35-GM146762-01 to JLVN) and by the Cancer Prevention and Research Institute of Texas (RR220033 to PR and RR210013 to JLVN). JLVN is a CPRIT Scholar in Cancer Research.
The HTML and PDF versions of the paper have been updated.
The authors regret the error.